15
Participants
Start Date
February 21, 2022
Primary Completion Date
May 1, 2022
Study Completion Date
January 1, 2023
Azvudine tablets(FNC) and Rilpivirine Tablets (RPV)
"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~FNC 3 mg (1 tablet)+RPV 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 10 consecutive days; RPV: 25 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days."
Azvudine tablets(FNC) and Rilpivirine Tablets (RPV)
"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10consecutive days; FNC 3 mg (1 tablet)+RPV 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 10 consecutive days; RPV: 25 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days."
Azvudine tablets (FNC) and Rilpivirine Tablets (RPV)
"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~RPV: 25 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; FNC 3 mg (1 tablet)+RPV 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 10 consecutive days."
Phase I Clinical Trial Research Center of Dongguan Kanghua Hospital, Guangdong
Henan Genuine Biotech Co., Ltd.
INDUSTRY